Is Sage Therapeutics, Inc. (SAGE) a Buy, Sell, or Hold?
Sage Therapeutics, Inc.
NASDAQ:SAGE
$5.47 USD
-$0.08 (-1.44%)
- Volume
- 327.13K
- Average Volume
- 736.37K
- Market Capitalization
- $334.62M
- P/E Ratio
- -0.99
- Dividend Yield
- 0.00%
- Price Target
- $28.00
- Year High
- $28.26
- Year Low
- $4.62
- Payout Ratio
- $0.00
- Current Ratio
- $10.02
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Market |
| CEO | Mr. Barry E. Greene |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SAGE |
| CUSIP | 78667J108 |
| CIK | 0001597553 |
| Web | https://www.sagerx.com |
| Phone | 617 299 8380 |
| Currency | USD |
| Employees | 487 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.02 |
| Quick Ratio | 10.02 |
| Cash Ratio | 1.65 |
Sales & Book Value
| Annual Sales | $86.46M |
| Price / Sales | 3.14 |
| Cash Flow | -5.24 |
| Price / Cash Flow | -1.05 |
| Price / Book | 0.61 |
Price Target and Rating
| Average Stock Price Forecast | $28.00 |
| High Stock Price Forecast | $105.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | -80.46% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-9.05 |
| Trailing P/E Ratio | -0.99 |
| PEG Ratio | -0.04 |
| P/E Growth | -0.04 |
| Net Income | $-541.49M |
| Net Margin | -317.29% |
| Pretax Margin | -317.29% |
| Return on Equity | -50.29% |
| Return on Assets | -54.24% |
Financials Score
| AltmanZ Score | -4.38 |
| Piotroski Score | 3.00 |
| Working Capital | 544.58M |
| Total Assets | 622.43M |
| Ebit | -372.72M |
| Market Cap | 334.62M |
| Total Liabilities | 70.6M |
Poll Results
About Sage Therapeutics, Inc. (NASDAQ:SAGE) Stock
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modul ... ator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
2024-11-26 07:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. A.
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
2024-11-21 12:01:25
Sage Therapeutics' pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntington's disease fails to meet the primary goal.
2024-11-20 10:36:13
On Wednesday, Sage Therapeutics Inc SAGE revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's Disease (HD), an inherited brain disorder that causes nerve cells in the brain to break down and die.
Sage Therapeutics to end Huntington's disease trial after key therapy fails again
2024-11-20 07:34:00
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer's disease.
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study
2024-11-20 06:58:51
Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington's disease after it failed a mid-stage study, the drug developer said on Wednesday.
Frequently Asked Questions
-
What is the current Sage Therapeutics, Inc. (SAGE) stock price?
-
Sage Therapeutics, Inc.(NASDAQ:SAGE) stock price is $5.47 in the last trading session. During the trading session, SAGE stock reached the peak price of $28.26 while $4.62 was the lowest point it dropped to. The percentage change in SAGE stock occurred in the recent session was --1.44% while the dollar amount for the price change in SAGE stock was -$-0.08.
-
SAGE's industry and sector of operation?
-
The NASDAQ listed SAGE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SAGE?
-
Mr. Christopher Benecchi | Chief Operating Officer
Dr. Laura Gault M.D., Ph.D. | Chief Medical Officer
Mr. Mike Quirk Ph.D. | Chief Scientific Officer
Ashley Kaplowitz | Director of Investor Relations
Mr. Gregory Shiferman | Senior Vice President & General Counsel -
How many employees does SAGE have?
-
Number of SAGE employees currently stands at 487. SAGE operates from 215 First Street, Cambridge, MA 02142, US.
-
Link for SAGE official website?
-
Official Website of SAGE is: https://www.sagerx.com
-
How do I contact SAGE?
-
SAGE could be contacted at phone #617 299 8380 and can also be accessed through its website. SAGE operates from 215 First Street, Cambridge, MA 02142, US.
-
How many shares of SAGE are traded daily?
-
The average number of SAGE shares traded daily for last 3 months was 736.37K.
-
What is the market cap of SAGE currently?
-
The market value of SAGE currently stands at $334.62M with its latest stock price at $5.47